Exelixis drug fails PhIII lung cancer trial with Cabometyx and Tecentriq combo
Exelixis’ trial of Cabometyx and Tecentriq for patients with metastatic non-small cell lung cancer failed to meet its goal of extending overall survival compared to chemotherapy.
The company shared the failure in a brief press release Thursday afternoon. It said it will share other, secondary outcomes at the trial at a future medical meeting.
The 366 patients in the trial received Exelixis’ drug Cabometyx in combination with Roche’s Tecentriq or docetaxel. All of the patients had been treated previously with anti-PD-1 or PD-L1 drugs that failed to stop their cancers.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.